Dossier
Daiichi Sankyo
Coverage of Daiichi Sankyo in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
The FDA approved Trutakna, a kidney disease drug from Vera Therapeutics, for treating IgA nephropathy at an annual price of $425,000. U.K. officials are finalizing a pricing deal with AstraZeneca and Daiichi Sankyo to provide access to Enhertu, a breast cancer drug previously deemed too costly for the U.K. market.
- Daiichi Sankyo Sees Strong Growth Despite One‑Off Costs
Daiichi Sankyo expects strong growth despite one-off costs. The company's financial performance is anticipated to be robust. Strong growth indicates a positive outlook for Daiichi Sankyo.